TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22317607

Group type: EXPERIMENTAL
Intervention: Labor Gym (LG) program
Number of subjects: 35
Study: 20553538

Group type: EXPERIMENTAL
Intervention: Health professional facilitated sessions (three one-hour group education and goal setting sessions over 7 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (one-hour health promotion talk)
Number of subjects: 121
Study: 18029171

Group type: EXPERIMENTAL
Intervention: Anastrozole (1mg, n=29)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5mg, n=29)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exemestane (25mg, n=32)
Number of subjects: 90
Study: 17174448

Group type: EXPERIMENTAL
Intervention: UVC disinfection
Number of subjects: 183

Group type: COMPARATOR
Intervention: Antiseptic wiping
Number of subjects: 183

Group type: COMPARATOR
Intervention: Dry wiping
Number of subjects: 183
Study: 15300210

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: IV opioids
Number of subjects: 46
Study: 12170987

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0
Study: 8922763

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg.kg‐1
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 70
Study: 1348403

Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 15

Group type: COMPARATOR
Intervention: digoxin
Number of subjects: 15
Study: 3994353

Group type: EXPERIMENTAL
Intervention: Intramuscular ceruletide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30343977

Group type: EXPERIMENTAL
Intervention: Telemedical follow-up
Number of subjects: 224

Group type: COMPARATOR
Intervention: Onsite follow-up
Number of subjects: 224
Study: 27738970

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both RYGB and SG
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Persistent diabetes post-operatively
Number of subjects: 14
Study: 27435894

Group type: EXPERIMENTAL
Intervention: Adenosine (4 to 512 μg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carotid body ablation
Number of subjects: 11
Study: 24296500

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High-P/B group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low-P/B group
Number of subjects: 62
Study: 22972843

Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate (PrEP)
Number of subjects: 0
Study: 19067728

Group type: EXPERIMENTAL
Intervention: Pegvisomant (20 mg daily for 14 days)
Number of subjects: 3
Study: 17457091

Group type: EXPERIMENTAL
Intervention: NNRTI-based regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: PI-based regimen
Number of subjects: 0
Study: 14969833

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/d administered preoperatively in HBV active replication group (15 recipients)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/d administered preoperatively in HBV inactive replication group (7 recipients)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (3 recipients)
Number of subjects: 25
Study: 11401118

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (n = 1,327)
Number of subjects: 9906

Group type: COMPARATOR
Intervention: Thrombolysis (n = 8,579)
Number of subjects: 9906
Study: 9072566

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL) monotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined percutaneous nephrostolithotomy with ESWL
Number of subjects: 50
Study: 8201485

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg intravenously at 6 to 12 postnatal hours and every 24 hours for two more doses)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 61
Study: 3310942

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg four times a day (short-term phase)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (short-term phase)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime (maintenance phase)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (maintenance phase)
Number of subjects: 104
Study: 29288590

Group type: EXPERIMENTAL
Intervention: Ampcare Effective Swallowing Protocol (ESP), treatment 5 days/week for 4 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (speech and language therapy dysphagia care).
Number of subjects: 30
Study: 27404223

Group type: EXPERIMENTAL
Intervention: Intralipid®
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24454698

Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Maximal volitional interval training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Walking (active control)
Number of subjects: 49
Study: 22623396

Group type: EXPERIMENTAL
Intervention: D2 at 5 μg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: D2 at 10 μg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: D3 at 5 μg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: D3 at 10 μg/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19395648

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18042229

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 100 units
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 15925520

Group type: EXPERIMENTAL
Intervention: Focused attention on a gap between collinear elements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divided attention between two gaps in the first stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conscious intention
Number of subjects: 0
Study: 12088961

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with epinephrine 5 microg/mL
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 46
Study: 10468078

Group type: EXPERIMENTAL
Intervention: Ir‐192
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8536304

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 2196522

Group type: EXPERIMENTAL
Intervention: Standard methylphenidate (twice a day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (SR-20 Ritalin)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sustained-release dextroamphetamine (Dexedrine Spansule)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pemoline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All four medications
Number of subjects: 22
Study: 39539

Group type: EXPERIMENTAL
Intervention: 0.1% dipivefrin
Number of subjects: 42

Group type: COMPARATOR
Intervention: 2% epinephrine hydrochloride
Number of subjects: 42
Study: 31975354

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 7.5 mg once daily
Number of subjects: 0
Study: 31521337

Group type: EXPERIMENTAL
Intervention: Early RIPC (remote ischaemic preconditioning)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Sham RIPC (control)
Number of subjects: 406
Study: 26130725

Group type: EXPERIMENTAL
Intervention: Nurse Case Management Plus Contingency Management (NCM + CM)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Standard Education Plus Contingency Management (SE + CM)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Both interventions (NCM + CM and SE + CM)
Number of subjects: 414
Study: 25798728

Group type: EXPERIMENTAL
Intervention: Turtle Program (n = 18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist Control (WLC; n = 22)
Number of subjects: 40
Study: 23448513

Group type: EXPERIMENTAL
Intervention: Anapen(®)
Number of subjects: 100

Group type: COMPARATOR
Intervention: EpiPen(®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 100
Study: 21056606

Group type: EXPERIMENTAL
Intervention: Pork meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chicken meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beef meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 30
Study: 19812866

Group type: EXPERIMENTAL
Intervention: 0.5% MSG in mashed potatoes
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MSG in spinach and ground beef (2%)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Foods without MSG
Number of subjects: 53
Study: 16970947

Group type: EXPERIMENTAL
Intervention: Moderate statin treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-treated hyperlipidemic group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: No lipoprotein abnormalities
Number of subjects: 48
Study: 15297280

Group type: EXPERIMENTAL
Intervention: Chronological reading
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Paired reading
Number of subjects: 166

Group type: COMPARATOR
Intervention: Comparison between chronological and paired reading
Number of subjects: 166
Study: 11730209

Group type: EXPERIMENTAL
Intervention: PG synthesis inhibitor (PGSI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 9103301

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 0
Study: 8229035

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (500 mg for five consecutive days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral methylprednisolone (500 mg for five consecutive days)
Number of subjects: 35
Study: 31679831

Group type: EXPERIMENTAL
Intervention: Suture Tunnel (ST)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Screw and Washer (SW)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Suture Anchor (SA)
Number of subjects: 24
Study: 31207148

Group type: EXPERIMENTAL
Intervention: Educational strategy intervention and remote supervision
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 169
Study: 28108578

Group type: EXPERIMENTAL
Intervention: Celite-guided anticoagulation
Number of subjects: 97

Group type: COMPARATOR
Intervention: Kaolin-guided anticoagulation
Number of subjects: 97
Study: 26206095

Group type: EXPERIMENTAL
Intervention: 750 μg vitamin D3
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: 1500 μg vitamin D3
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 23642949

Group type: EXPERIMENTAL
Intervention: Caralluma fimbriata extract (500 mg capsules twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (500 mg capsules twice daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Caralluma fimbriata extract
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both groups (Caralluma fimbriata extract and placebo)
Number of subjects: 33
Study: 22137514

Group type: EXPERIMENTAL
Intervention: Stimulating catheters (Group SC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonstimulating catheters (Group NSC)
Number of subjects: 40
Study: 19506494

Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) training program combined with conventional rehabilitation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 14
Study: 17252909

Group type: EXPERIMENTAL
Intervention: High dose of pulsed low frequency magnetic field (PLFMF) with kinesitherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low dose of pulsed low frequency magnetic field (PLFMF) with kinesitherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group treated only with kinesitherapy
Number of subjects: 90
Study: 15580064

Group type: EXPERIMENTAL
Intervention: Nutritional counselling by dietician
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Nutritional counselling by general practitioner (GP)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Nutritional counselling by GP
Number of subjects: 503
Study: 10889097

Group type: EXPERIMENTAL
Intervention: Cataract extraction or secondary lens implantation
Number of subjects: 854
Study: 9055905

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at daily doses of 0.1, 0.2, or 0.3 IU/kg (0.033, 0.067, or 0.1 mg/kg) s.c.
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 244
Study: 1390340

Group type: EXPERIMENTAL
Intervention: Twice daily oral ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three times daily oral ondansetron
Number of subjects: 0
Study: 2409278

Group type: EXPERIMENTAL
Intervention: 32% dextran 70 (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 32% dextran 70
Number of subjects: 22
Study: 3493519

Group type: EXPERIMENTAL
Intervention: Beta-lactamase-susceptible agents
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beta-lactamase-producing strains
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 20
Study: 29709434

Group type: EXPERIMENTAL
Intervention: Ambient music
Number of subjects: 182
Study: 27794201

Group type: EXPERIMENTAL
Intervention: Moderate red wine intake for 1 month
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no wine intake)
Number of subjects: 20
Study: 25958941

Group type: EXPERIMENTAL
Intervention: 0.7g CHO.kg(‐1) supplement
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.35g CHO.kg(‐1) supplement
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dietary records of CHO intake
Number of subjects: 49
Study: 23030767

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg QD
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 22017336

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18293379

Group type: EXPERIMENTAL
Intervention: Intensive myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHCR)
Number of subjects: 21
Study: 16267121

Group type: EXPERIMENTAL
Intervention: Cued targets (repeated targets)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Catch targets
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pursuit latency across repeated targets
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unexpected first targets
Number of subjects: 28
Study: 15074452

Group type: EXPERIMENTAL
Intervention: Ventilation-feedback with exercise (V(+EX))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exercise only (EX(ONLY))
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ventilation-feedback only (VF(ONLY))
Number of subjects: 39
Study: 10717717

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 240 mg daily for 3 days (group B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg daily for 3 days (group C)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo for 3 days (group A)
Number of subjects: 58
Study: 9165601

Group type: EXPERIMENTAL
Intervention: Maximal bladder distension (voiding postponement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal bladder filling (regular and frequent voidings)
Number of subjects: 0
Study: 1312317

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (18 Max-EPA capsules daily, 3.24 g eicosapentaenoic acid, 2.16 g docosahexaenoic acid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 18
Study: 2997764

Group type: EXPERIMENTAL
Intervention: Microcrystalline hydroxyapatite compound (MCHC)
Number of subjects: 36
Study: 30758848

Group type: EXPERIMENTAL
Intervention: GTR (Guided Tissue Regeneration) with resorbable collagen membrane
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no collagen membrane)
Number of subjects: 32
Study: 28382392

Group type: EXPERIMENTAL
Intervention: Silicon nitride implants
Number of subjects: 100

Group type: COMPARATOR
Intervention: PEEK cages filled with autograft
Number of subjects: 100
Study: 25456166

Group type: EXPERIMENTAL
Intervention: Daily 0.1-mg subcutaneous GnRHa until day of beta-HCG (n = 224)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Daily vaginal progesterone suppositories (both groups)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Stopped GnRHa on day of HCG injection (n = 222)
Number of subjects: 446
Study: 23574148

Group type: EXPERIMENTAL
Intervention: Pre-emptive antifungal treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no antifungal treatment)
Number of subjects: 81
Study: 20097587

Group type: EXPERIMENTAL
Intervention: Cetirizine 0.4 mg/kg orally twice daily for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protection blankets and stabling
Number of subjects: 0
Study: 19072745

Group type: EXPERIMENTAL
Intervention: Prior spontaneous preterm birth at <24 weeks
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Most recent birth at <24 weeks
Number of subjects: 1014
Study: 18007138

Group type: EXPERIMENTAL
Intervention: Prepregnancy counselling and multidisciplinary team management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral hypoglycaemics like metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with established diabetes taking folic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with established diabetes with documentation of glycaemic control before pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NHS trusts providing multidisciplinary preconception services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caesarean delivery rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congenital malformation rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perinatal mortality rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stillbirth rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant mortality in the first 3 months of life
Number of subjects: 0
Study: 15096078

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11917051

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg added to ACEI regimen
Number of subjects: 60
Study: 10178713

Group type: EXPERIMENTAL
Intervention: iMg++ group (n=65)
Number of subjects: 150

Group type: COMPARATOR
Intervention: tMg++ group (n=85)
Number of subjects: 150
Study: 7657007

Group type: EXPERIMENTAL
Intervention: Expectant management with tocolysis for 48 hours if necessary (Group A)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Aggressive tocolysis (Group B)
Number of subjects: 241
Study: 2495811

Group type: EXPERIMENTAL
Intervention: Alfentanil 75 micrograms kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study: 737474

Group type: EXPERIMENTAL
Intervention: Guar crispbread
Number of subjects: 9
Study: 30946525

Group type: EXPERIMENTAL
Intervention: 4 mg extended-release tolterodine at bedtime
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 172
Study: 27714955

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (lowNa)
Number of subjects: 9

Group type: COMPARATOR
Intervention: High-sodium diet (highNa)
Number of subjects: 9
Study: 25960284

Group type: EXPERIMENTAL
Intervention: Combination therapy (andrographolide sulfonate plus conventional therapy)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 46
Study: 24067111

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff pressure maintained at 20 mm Hg after retractor placement
Number of subjects: 177

Group type: COMPARATOR
Intervention: Endotracheal tube cuff pressure not adjusted after retractor placement
Number of subjects: 177
Study: 21843745

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Work and Social Adjustment Scale (WSAS)
Number of subjects: 1023
Study: 19478701

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (n=41)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Halothane anesthesia (n=42)
Number of subjects: 83
Study: 17955786

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (EPA and DHA)
Number of subjects: 0
Study: 14765872

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Gamma Nail (GN)
Number of subjects: 424
Study: 11701070

Group type: EXPERIMENTAL
Intervention: Megadose steroid therapy (group S)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lipoprostaglandin E(1) therapy (group L)
Number of subjects: 31
Study: 9337183

Group type: EXPERIMENTAL
Intervention: KCl infusion (maximum, 40 mEq) in healthy subjects treated with quinidine sulfate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: KCl infusion (maximum, 40 mEq) in CHF patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20
Study: 7887823

Group type: EXPERIMENTAL
Intervention: Filling the dialysis circuit with 6.7% human albumin in saline for 10 min at a flow rate of 100 ml/min before HD
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard hemodialysis without albumin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Filling the dialysis circuit with albumin
Number of subjects: 8